GlassScriptPhysician profile
Young Ah Lee
NPI 1093945883
$2,836.14
in general payments reported to CMS, 2019-2025
25 companies · $195 in 2025
The $195 reported for 2025 was less than what a typical Neurology With Special Qualifications In Child Neurology provider received nationally (typical 2025 total: $275).
See the full distribution for Neurology with Special Qualifications in Child Neurology
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $164 · 2020: $1,458 · 2021: $115 · 2022: $50.26 · 2023: $453 · 2024: $401 · 2025: $195.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,049.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,049.24 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Livanova USA, INC. | $1,443.73 | 2020-2021 | |
| Jazz Pharmaceuticals INC. | $229.55 | 2023-2025 | |
| Ucb, INC. | $213.05 | 2020-2025 | Fintepla, Briviact, Rystiggo |
| Immedica Pharma US, INC. | $127.84 | 2024 | |
| Vericel Corporation | $119.37 | 2019 | |
| Acadia Pharmaceuticals INC | $110.54 | 2023-2024 | Daybue |
| Neurelis, INC. | $106.87 | 2021-2023 | Valtoco |
| Emd Serono, INC. | $53.56 | 2025 | |
| Vanda Pharmaceuticals INC. | $52.77 | 2024-2025 | Ponvory |
| Salvin Dental Specialties, INC. | $44.52 | 2019 | |
| Mallinckrodt Hospital Products INC. | $39.98 | 2024-2025 | Acthar |
| Greenwich Biosciences, INC. | $38.34 | 2021 | |
| Sunovion Pharmaceuticals INC. | $35.27 | 2022 | |
| Abbvie INC. | $25.91 | 2024 | |
| Zogenix INC. | $23.91 | 2021 |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sk Life Science, INC. | $21.42 | 2023 | |
| Sumitomo Pharma America, INC. | $19.38 | 2023 | Aptiom |
| Amneal Pharmaceuticals LLC | $18.53 | 2023 | Lyvispah |
| Alexion Pharmaceuticals, INC. | $17.73 | 2024 | Ultomiris |
| Astrazeneca Pharmaceuticals LP | $17.09 | 2021 | |
| Biomarin Pharmaceutical INC. | $17.04 | 2024 | Brineura |
| Azurity Pharmaceuticals, INC. | $16.95 | 2024 | Zonisade |
| Travere Therapeutics, INC. | $14.99 | 2022 | |
| Advanced Respiratory, INC | $14.20 | 2020 | |
| Lilly USA, LLC | $13.60 | 2025 | Kisunla |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Young Lee listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.